MedTrace Logo

A Clinical Study of V540A in Healthy Female Participants (V540A-005)

NCT07224477 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 525

Last updated 2026-02-19

No results posted yet for this study

Summary

Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV.

A standard vaccine to prevent HPV-related cancers is V503. V503 protects against 9 types of HPV. V540A is a study vaccine designed to protect against the same (shared) 9 HPV types plus other (unique) HPV types.

Researchers want to learn if V540A:

* Is safe and if people tolerate it
* Works as well as V503 to cause an immune response (the body's response to protect against infections and illnesses) to the shared HPV types.

Conditions

  • Healthy

Interventions

BIOLOGICAL

V540A-2

Suspension administered via intramuscular (IM) injection.

BIOLOGICAL

V540A-3

Suspension administered via intramuscular (IM) injection.

BIOLOGICAL

GARDASIL®9

Suspension administered via IM injection.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
26 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-20
Primary Completion
2028-04-04
Completion
2028-04-04
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07224477 on ClinicalTrials.gov